Characteristics of previous meta-analyses of the role of vitamin D status in hematological malignancies
| Study . | Disease . | No. of articles included . | HR (95% CI) . |
|---|---|---|---|
| This study | Myeloid malignancy | 5 | OS, 1.39 (1.06-1.82); PFS, 2.03 (1.23-3.32) |
| Lymphoid malignancy | 20 | OS, 2.07 (1.79-2.40); PFS, 1.91 (1.61-2.25) | |
| ASCT | 3 | OS, 1.65 (1.04-2.61) | |
| Allo-HSCT | 3 | OS, 1.50 (1.03-2.18) | |
| Tao et al, 202174 | Lymphoma | 12 | OS, 1.94 (1.71-2.19); PFS, 2.06 (1.82-2.32) |
| Chiengthong et al, 202079 | HSCT | 8 | aGVHD, 1.07 (0.74-1.53); cGVHD, 1.75 (0.72-4.26) |
| Wang et al, 201510 | Hematological cancers | 7 | OS, 1.85 (1.54-2.23); RFS, 1.45 (1.25-1.70) |
| Leukemia | 3 | OS, 2.17 (1.54-3.05); RFS, 1.74 (1.34-2.27) | |
| Lymphoma | 4 | OS, 1.95 (1.47-2.59); RFS, 1.25 (1.02-1.54) | |
| Li et al, 20145 | Lymphoma | 2 | OS, 2.08 (1.56-2.78) |
| Study . | Disease . | No. of articles included . | HR (95% CI) . |
|---|---|---|---|
| This study | Myeloid malignancy | 5 | OS, 1.39 (1.06-1.82); PFS, 2.03 (1.23-3.32) |
| Lymphoid malignancy | 20 | OS, 2.07 (1.79-2.40); PFS, 1.91 (1.61-2.25) | |
| ASCT | 3 | OS, 1.65 (1.04-2.61) | |
| Allo-HSCT | 3 | OS, 1.50 (1.03-2.18) | |
| Tao et al, 202174 | Lymphoma | 12 | OS, 1.94 (1.71-2.19); PFS, 2.06 (1.82-2.32) |
| Chiengthong et al, 202079 | HSCT | 8 | aGVHD, 1.07 (0.74-1.53); cGVHD, 1.75 (0.72-4.26) |
| Wang et al, 201510 | Hematological cancers | 7 | OS, 1.85 (1.54-2.23); RFS, 1.45 (1.25-1.70) |
| Leukemia | 3 | OS, 2.17 (1.54-3.05); RFS, 1.74 (1.34-2.27) | |
| Lymphoma | 4 | OS, 1.95 (1.47-2.59); RFS, 1.25 (1.02-1.54) | |
| Li et al, 20145 | Lymphoma | 2 | OS, 2.08 (1.56-2.78) |
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; RFS, relapse-free survival.